169 related articles for article (PubMed ID: 31847742)
1. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.
Lutrino ES; Orlando L; Febbraro A; Giampaglia M; Zamagni C; Schiavone P; Scavelli C; Dima G; Fedele P; Giordano G; Bilancia D; Quaranta AM; Rubino D; Filippelli G; Fontanella C; Caliolo C; Marino A; Calvani N; Ferrara P; Cinieri S
Tumori; 2020 Aug; 106(4):301-305. PubMed ID: 31847742
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Sarici F; Altundag K
J BUON; 2020; 25(6):2562-2569. PubMed ID: 33455097
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Yamashita T; Kawaguchi H; Masuda N; Kitada M; Narui K; Hattori M; Yoshinami T; Matsunami N; Yanagihara K; Kawasoe T; Nagashima T; Bando H; Yano H; Hasegawa Y; Nakamura R; Kashiwaba M; Morita S; Ohno S; Toi M
Invest New Drugs; 2021 Feb; 39(1):217-225. PubMed ID: 32833136
[TBL] [Abstract][Full Text] [Related]
4. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
[TBL] [Abstract][Full Text] [Related]
5. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
Sakaguchi K; Nakatsukasa K; Koyama H; Kato M; Sakuyama A; Matsuda T; Tsunoda N; Fujiwara I; Yamaguchi M; Tanaka H; Onishi K; Onishi M; Yoshino Y; Kikuchi T; Taguchi T
Anticancer Res; 2018 Jul; 38(7):4073-4081. PubMed ID: 29970533
[TBL] [Abstract][Full Text] [Related]
6. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
[TBL] [Abstract][Full Text] [Related]
7. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
9. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
10. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
[TBL] [Abstract][Full Text] [Related]
14. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
16. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Gavilá J; De La Haba J; Bermejo B; Rodríguez-Lescure Á; Antón A; Ciruelos E; Brunet J; Muñoz-Couselo E; Santisteban M; Rodríguez Sánchez CA; Santaballa A; Sánchez Rovira P; García Sáenz JÁ; Ruiz-Borrego M; Guerrero-Zotano AL; Huerta M; Cotes-Sanchís A; Lao Romera J; Aguirre E; Cortés J; Llombart-Cussac A
Clin Transl Oncol; 2020 Mar; 22(3):420-428. PubMed ID: 31203575
[TBL] [Abstract][Full Text] [Related]
17. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
[TBL] [Abstract][Full Text] [Related]
18. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
19. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB; Fernández-Ortega A; Stradella A; Morilla I; Falo C; Vázquez S; Castany R; Villanueva R; Recalde S; Pérez VN; Gil-Gil M; Pernas S
BMC Pharmacol Toxicol; 2019 Nov; 20(1):68. PubMed ID: 31753013
[TBL] [Abstract][Full Text] [Related]
20. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
